Impress-norway: improving public cancer care by implementing precision medicine in norway; inclusion rates and preliminary results

HIGHLIGHTS

• What: The aim of the IMPRESS-Norway trial is to facilitate patient access to commercially available targeted anticancer therapies, and to describe anti-tumour activity and toxicity of targeted therapies. The trial is still recruiting patients, and the final data_analysis will be presented at the later time point. This study reports on the primary endpoint of the IMPRESS-Norway trial per October 1, 2023. Primary study endpoints are: 1) percentage of the patients included in the trial based on their molecular profile, and 2) disease control rate (DCR) defined as objective complete response (CR), partial response (PR . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.